Wee Ric Kim

Wee Ric Kim

Auto-generated profile, based on publicly available information

Wee Ric Kim

Digital Health Division , Ministry of Health Malaysia, Wilayah Persekutuan Putrajaya, Malaysia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ELEe Vien Low
Ee Vien Low
MPMohan Dass Pathmanathan
Mohan Dass Pathmanathan
SCSuresh Kumar Chidambaram
Suresh Kumar Chidambaram
WKWee Ric Kim
Wee Ric Kim
WLWei Jia Lee
Wei Jia Lee
KPKalaiarasu M. Peariasamy
Kalaiarasu M. Peariasamy
To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death. This 1:1 propensity score matched cohort study from 647 public health clinics in Malaysia included all patients with COVID-19 with positive tests aged 18 years and older, who were eligible for nirmatrelvir-ritonavir treatment within 5 days of illness from July 14, 2022, to November 14, 2022. The exposed group was patients with COVID-19 initiated with nirmatrelvir-ritonavir treatment, whereas those not initiated with the drug served as the control group. Data was analyzed from July 14, 2022 to December 31, 2022. A total of 20,966 COVID-19 high-risk outpatients (n = 10,483 for nirmatrelvir-ritonavir group and n = 10,483 for control group) were included in the study. Nirmatrelvir-ritonavir treatment was associated with a 36% reduction (adjusted hazard ratio 0.64 [95% CI 0.43, 0.94]) in hospitalization compared with those not given the drug. There was a single ICU admission for the control group and one death each was reported in the nirmatrelvir-ritonavir and control group, respectively. Nirmatrelvir-ritonavir treatment was associated with reduced hospitalization in high-risk patients with COVID-19 even in highly vaccinated populations.

10 May 2024 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
ELEe Vien Low
Ee Vien Low
HTHoon Shien Teh
Hoon Shien Teh
NHNicholas Yee Liang Hing
Nicholas Yee Liang Hing
SCSuresh Kumar Chidambaram
Suresh Kumar Chidambaram
MPMohan Dass Pathmanathan
Mohan Dass Pathmanathan
KPKalaiarasu M. Peariasamy
Kalaiarasu M. Peariasamy
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir within 5 days of a COVID-19 illness in order to avert hospitalization within a 30-day period in the Malaysia setting; (ii) determine how variations in pricing and hospitalization rates will affect the cost-effectiveness of nirmatrelvir/ritonavir. Methods The 30-day hospitalization related to COVID-19 was determined using 1 to 1 propensity score-matched real-world data in Malaysia from 14 July 2022 to 14 November 2022. To determine the total per-person costs related to COVID-19, we added the cost of drug (nirmatrelvir/ritonavir or control), clinic visits and inpatient care. Incremental cost-effectiveness ratio (ICER) per hospitalization averted was calculated. Results Our cohort included 31,487 patients. The rate of hospitalization within 30 days was found to be 0.35% for the group treated with nirmatrelvir/ritonavir, and 0.52% for the control group. The nirmatrelvir/ritonavir group cost an additional MYR 1,625.72 (USD 358.88) per patient. This treatment also resulted in a reduction of 0.17% risk for hospitalization, which corresponded to an ICER of MYR 946,801.26 (USD 209,006.90) per hospitalization averted. Conclusion In Malaysia, where vaccination rates were high, nirmatrelvir/ritonavir has been shown to be beneficial in the outpatient treatment of adults with COVID-19 who have risk factors; however, it was only marginally cost effective against hospitalization for healthy adults during the Omicron period.

16 February 2022 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
HSHans Prakash Sathasivam
Hans Prakash Sathasivam
SCSelina Yuet Ling Chew
Selina Yuet Ling Chew
WKWee‐Ric Kim
Wee‐Ric Kim
CSChee‐Lynn Saw
Chee‐Lynn Saw
LTLu Ping Tan
Lu Ping Tan
AKAlan Khoo
Alan Khoo